Compare Quest Diagnostics Inc (DGX) vs Global X Uranium ETF (URA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Global X Uranium ETF — how do they compare? Quest Diagnostics Inc trades at $204.2 (market cap $22.80B), while Global X Uranium ETF trades at $40.89. The key difference: Quest Diagnostics Inc pays a 1.67% dividend while Global X Uranium ETF pays none, and Quest Diagnostics Inc is trading nearer its 52-week high, Global X Uranium ETF nearer its low. Which is the better fit depends on your goals.
| DGX | URA | |
|---|---|---|
Market Cap | $22.80B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $216.02 | $61.81 |
52-Week Low | $166.42 | $36.45 |
Enterprise Value | $28.82B | — |
Dividend Yield | 1.67% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
URA (Global X Uranium ETF) trades at $40.72, down 5.24% over 24 hours amid bearish technical signals. The ETF faces selling pressure with all 13 moving averages signaling bearish momentum, though RSI indicators suggest potential oversold conditions. Recent news highlights uranium's strategic positioning at the intersection of AI power demand and nuclear energy revival, with the fund holding $6.29 billion in assets across 56 uranium-related companies.
The ETF's outlook balances near-term technical weakness against strong secular tailwinds from AI-driven electricity demand and nuclear policy support. Key risks include uranium price volatility and competition from pure-miner alternatives, while the current oversold technical condition may present entry opportunities for long-term investors betting on nuclear energy adoption.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Global X Uranium ETF
URA provides broad exposure to the global uranium industry and nuclear energy sector. Unlike pure-play mining funds, it includes companies involved in nuclear component production and infrastructure, with top 2026 holdings such as Cameco, Oklo, and Uranium Energy Corp.
Read more on URA →
